Medication info

Rinatry Duo Tablets 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Bionex Co., Ltd.
Appearance
Bright orange oval film-coated tablets
Packaging
60 tablets/box [(10 tablets/PTP × 6)]
Approval status
Active

MFDS item code 202001310 · Approved 2020.02.24

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. Dose increases should be made gradually to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no history of previous antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients with inadequate glycemic control on concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not Administer to the Following Patients).

Ingredients

Manufacturer
Bionex Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty controlling blood sugar
View approved original text

This medication is used along with diet and exercise to help control blood sugar in adults with type 2 diabetes. It can be administered to individuals who have not previously received diabetes medication or who find blood sugar control difficult with monotherapy. Additionally, this medication may be used in combination for individuals who do not achieve adequate efficacy with metformin monotherapy or the combination of metformin and other medications. For instance, it can be combined with sulfonylureas, insulin, empagliflozin, etc. This therapy helps to more effectively manage blood sugar levels. This medication improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. Dose increases should be made gradually to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently receiving metformin: For patients with no history of previous antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients with inadequate glycemic control on concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's previous metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not Administer to the Following Patients).

Precautions

This medication helps control blood sugar levels. However, the use of this medication can rarely lead to serious side effects such as lactic acidosis, which may result in death. This medication should not be used in patients with an allergy to its components or in those with type 1 diabetes, lactic acidosis, or severe renal impairment. Patients in acute conditions such as dehydration, severe infection, or acute myocardial infarction should also exercise caution. When used with other medications that may cause hypoglycemia, there is an increased risk of hypoglycemia, so caution is necessary. Patients with decreased renal function should undergo regular renal function tests, and this medication should not be taken in cases of severe renal impairment. Patients with impaired heart function should periodically monitor heart and kidney function while using this medication, and the intake of this medication should be temporarily stopped before and after surgery or radiological examinations. During treatment with this medication, rare side effects such as pancreatitis or bullous pemphigoid may occur, so if abdominal pain or skin abnormalities occur, consult a doctor immediately. The metformin ingredient may lower vitamin B12 levels, so it is advisable to periodically check vitamin B12 levels during long-term use. Women who are pregnant or may become pregnant, as well as breastfeeding mothers, should not use this medication. It is not recommended for children and adolescents as safety and effectiveness have not been established. Elderly patients commonly have decreased renal function, so appropriate dosing should be determined based on renal function, and regular tests are necessary. In cases of overdose, there may be an increased risk of lactic acidosis, so it is important to strictly adhere to the prescribed dose. This medication should be stored in a sealed container, protected from moisture and direct sunlight, and should not be transferred to another container.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decrease and deficiency of vitamin B12
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 120 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid-like eruption
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • concussion
  • palpitations
  • dry eye
  • cataracts
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • abdominal pressure urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • fatty liver
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid enlargement
  • anemia
  • headache
  • drowsiness
  • chest discomfort
  • asthenia
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • nasal bleeding
  • hypertension
  • insomnia
  • depression
  • anxiety
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyps
  • gingivitis
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • delirium
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. The recommended storage temperature is between 1 to 30 degrees Celsius at room temperature. This helps maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Bright orange oval film-coated tablets

Package unit

60 tablets/box [(10 tablets/PTP × 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.